Pinpoint Therapeutics believes that the company’s approach to treat therapy-resistant cancers also may be effective against COVID-19.
Researchers Develop New Class of Lung Cancer Drugs
Chemotherapy, Clinical Trials, Drug-resistant tumors, Francis Crick Institute, G12C KRAS inhibitors, IGF1R Pathway, KRAS gene, KRAS Mutations, Lung adenocarcinoma, Lung Cancer, mTOR Pathway, Mutations, R&D, Researchers, Science Translational Medicine, The Institute of Cancer Research (ICR)Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.